Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features

• Date:
  Friday, 29 November 2019
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

The aim of the workshop is to investigate the feasibility of using disease registries for cancer therapies based on genetic and molecular features.

The objectives are to agree on:

• core data elements that should be collected in cancer registries to support regulatory assessment of long term safety and effectiveness of new cancer treatments;
• quality assurance measures necessary to ensure registry data are of suitable quality to support regulatory evaluation and to permit registries interoperability;
• practical considerations for accessing and sharing data to be used for regulatory purposes.

Documents

Report of the workshop on the use of registries in the monitoring of cancer therapies based on tumours’ genetic and molecular features - 29 November 2019

Reference Number: EMA/661159/2019

Agenda - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features

Reference Number: EMA/499786/2019

Presentation - Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features: Introduction from the chair (Peter Mol)

Presentation - A regulatory view on the role of registries for generating data on cancer therapies (Filip Josephson)

Presentation - The European Network of Cancer Registries (ENCR) (Otto Visser)

Presentation - Registries for European Reference Networks (ERNs) (Hélène Le Borgne)

Presentation - The National Cancer Registration and Analysis Service (NCRAS) England: Data collection for tumour agnostic treatments (Alice Turnbull)